These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1936756)

  • 1. [Significance of the degree of oxidative hepatic metabolism in conditioning the pharmacokinetics and the pharmacodynamics of propafenone].
    Boriani G; Capucci A; Strocchi E; Marchesini B; Baroni M; Frabetti L; Ambrosioni E; Magnani B
    G Ital Cardiol; 1991 May; 21(5):517-26. PubMed ID: 1936756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Determination of oxidative phenotype in a sample population and correlation with the pharmacokinetics of propafenone].
    Boriani G; Strocchi E; Capucci A; Boschi S; Frabetti L; Ambrosioni E; Magnani B
    Cardiologia; 1990 Feb; 35(2):163-9. PubMed ID: 2208201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-state plasma concentrations of propafenone--chirality and metabolism.
    Volz M; Mitrovic V; Schlepper M
    Int J Clin Pharmacol Ther; 1994 Jul; 32(7):370-5. PubMed ID: 7952800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of the efficacy/tolerability ratio of cibenzoline and propafenone in the treatment of ventricular arrhythmia].
    Babuty D; Cosnay P; Rouesnel P; Bine-Scheck F; Arnaud R; Fauchier JP
    Ann Cardiol Angeiol (Paris); 1992 Apr; 41(4):225-34. PubMed ID: 1642441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of the anti-arrhythmic action of propafenone treatment and its influence on left ventricular function].
    Saitta A; Bonaiuto M; Mileto A; Oriti S; Cinquegrani M; Giordano G; Fodale P; Saitta M; Squadrito F
    Clin Ter; 1993 Apr; 142(4):351-60. PubMed ID: 8330479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Digoxin-propafenone interaction: values and limitations of plasma determination of the 2 drugs. Anti-arrhythmia effectiveness of propafenone].
    Palumbo E; Svetoni N; Casini M; Spargi T; Biagi G; Martelli F; Lanzetta T
    G Ital Cardiol; 1986 Oct; 16(10):855-62. PubMed ID: 3817368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man.
    Brode E; Müller-Peltzer H; Hollmann M
    Methods Find Exp Clin Pharmacol; 1988 Nov; 10(11):717-27. PubMed ID: 3221745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Propafenone and flecainide in the therapy of ventricular arrhythmias].
    Paperini L; Davini A; Lattanzi F; Topi A; Reisenhofer B; Squarcini G; Paci A; Topi PL
    Minerva Cardioangiol; 1995 Oct; 43(10):449-57. PubMed ID: 8819814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study].
    Lardoux H; Maison Blanche P; Marchand X; Canler A; Rouesnel P; Bleinc D; Péraudeau P; Scheck F
    Ann Cardiol Angeiol (Paris); 1996 Oct; 45(8):469-79. PubMed ID: 8952741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
    McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
    Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flecainide acetate: concentration-response relationships for antiarrhythmic and electrocardiographic effects.
    Boriani G; Capucci A; Strocchi E; Calliva R; Santarelli A; Biffi M; Magnani B
    Int J Clin Pharmacol Res; 1993; 13(4):211-9. PubMed ID: 8150547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites.
    Botsch S; Gautier JC; Beaune P; Eichelbaum M; Kroemer HK
    Mol Pharmacol; 1993 Jan; 43(1):120-6. PubMed ID: 8423765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.
    Siddoway LA; Thompson KA; McAllister CB; Wang T; Wilkinson GR; Roden DM; Woosley RL
    Circulation; 1987 Apr; 75(4):785-91. PubMed ID: 3829342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetics of oral propafenone in patients with supraventricular arrhythmia].
    Buoncuore A; Poirier JM; Jaillon P; Ferry A; Pochmalicki G; Colombel B; Vrancea F; Cheymol G; Valty J
    Therapie; 1989; 44(2):79-85. PubMed ID: 2756523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
    Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M
    Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diprafenone--comparative study of anti-arrhythmia therapy with propafenone].
    Geibel A; Zehender M; Hohnloser S; Landsrath C; Meinertz T; Just H
    Z Kardiol; 1988 Jul; 77(7):464-9. PubMed ID: 2463720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sotalol, propafenone, and flecainide: compared multiparametric analysis of ventricular repolarization in subjects without organic cardiopathy].
    Sarubbi B; Ducceschi V; Briglia N; Esposito R; Mayer MS; Scialdone A; Santangelo L; Iacono A
    Cardiologia; 1996 Jul; 41(7):645-51. PubMed ID: 8983831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous modeling of pharmacokinetics and pharmacodynamics of propafenone in healthy subjects.
    Cai WM; Zhang YD; Chen B; Cai MH; Luo JP; Ling SS
    Acta Pharmacol Sin; 2001 Oct; 22(10):956-60. PubMed ID: 11749782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of CYP2D6*10 genotype on propafenone pharmacodynamics in Chinese patients with ventricular arrhythmia.
    Cai WM; Xu J; Chen B; Zhang FM; Huang YZ; Zhang YD
    Acta Pharmacol Sin; 2002 Nov; 23(11):1040-4. PubMed ID: 12421483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.